The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma

被引：2
作者：
Naparstek E. [1 ]
机构：
[1] Department of Hematology and BMT, Tel Aviv Sourasky Medical Center, Tel Aviv University
来源：
Current Hematologic Malignancy Reports | 2006年 / 1卷 / 4期
关键词：
Overall Survival; Stem Cell Transplantation; Follicular Lymphoma; Mantle Cell Lymphoma; Autologous Stem Cell Transplantation;
D O I：
10.1007/s11899-006-0003-x
中图分类号：
学科分类号：
摘要：
The addition of rituximab to chemotherapy has substantially changed the treatment strategies for patients with B-cell lymphomas. Rituximab, combined with standard chemotherapy regimens, shows consistently improved results compared with chemotherapy alone and has been extensively employed in both newly diagnosed and relapsed patients with B-cell lymphoma. Because of its low toxicity profile and its potent antilymphoma activity mediated through direct apoptotic and indirect effector mechanisms, rituximab also has been actively incorporated into stem cell transplantation (SCT) protocols to attain a state of minimal disease, provide a safe and effective method for in vivo purging prior to autologous SCT, and promote graft-versus-lymphoma effects in allogeneic SCT. This review compiles the still immature but rapidly growing data on this combined modality. Copyright © 2006 by Current Science Inc.
引用
收藏
页码：220 / 229
页数：9
相关论文
共 63 条
  • [1] Vose J.M., Rizzo D.J., Tao-Wu J., Et al., Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission, Biol Blood Marrow Transplant, 10, pp. 116-127, (2004)
  • [2] Lenz G., Dreyling M., Schiegnitz E., Et al., Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group, Blood, 104, pp. 2667-2674, (2004)
  • [3] Deconinck E., Foussard C., Milpied N., Et al., High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS, Blood, 105, pp. 3817-3823, (2005)
  • [4] Kiss T.L., Mollee P., Lazarus H.M., Lipton J.H., Stem cell transplantation in mantle cell lymphoma: If, when and how?, Bone Marrow Transplant, 36, pp. 655-661, (2005)
  • [5] Grigg A., Ritchie D., Graft-versus-lymphoma effects: Clinical review, policy proposals, and immunobiology, Biol Blood Marrow Transplant, 10, pp. 579-590, (2004)
  • [6] Van Besien K., Loberiz F.E., Bajorunaite R., Et al., Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma, Blood, 10, pp. 3521-3529, (2003)
  • [7] Morris E.M., Mackinnon S., Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma, Best Pract Res Clin Haematol, 18, pp. 129-142, (2005)
  • [8] Buske C., Weigert O., Dryling M., Et al., Current status and perspective of antibody therapy in follicular lymphoma, Haematologica, 91, pp. 104-112, (2006)
  • [9] Kewalramani T., Zelenetz A.D., Nimer S.D., Et al., Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma, Blood, 103, pp. 3684-3688, (2004)
  • [10] Lenz G., Dreyling M., Hoster E., Et al., Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG), J Clin Oncol, 23, pp. 1984-1992, (2005)
1234567